IRIS
PICCO, AGNESE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.303
Totale 5.303
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.303
Totale 5.303
Salva come PNG Salva come JPEG
Città #
Genova 3.971
Rapallo 661
Genoa 512
Vado Ligure 142
Bordighera 17
Totale 5.303
Salva come PNG Salva come JPEG
Nome #
Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. 165
A normative study of the Italian printed word version of the free and cued selective reminding test 149
Brain 18F-DOPA PET and cognition in de novo Parkinson's disease. 146
Amyloid positron emission tomography and cognitive reserve. 144
Brain Functional Network in Alzheimer’s Disease: Diagnostic Markers for Diagnosis and Monitoring 133
Brain dopaminergic (FluroDOPA PET) correlates of kinematic flexibility in Parkinson's Disease 128
Neuroimaging findings in mild cognitive impairment 127
Nigro-caudate dopaminergic deafferentation: A marker of REM sleep behavior disorder? 121
FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort 121
The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: An EADC study 119
Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD 118
What predicts cognitive decline in de novo Parkinson's disease? 117
Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers 117
Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD 112
Parkinson’s Disease Sleep Scale 2: application in an Italian population 111
Seizures can precede cognitive symptoms in late-onset Alzheimer's disease. 110
Correlation between Doppler velocities and duplex ultrasound carotid cross-sectional percent stenosis. 109
Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. 109
Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study 109
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes 109
Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype. 109
The role of the serotonergic system in REM sleep behavior disorder 108
Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. 107
Early identification of MCI converting to AD: a FDG PET study 102
Screening of Early and Late Onset Alzheimer's Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy. 99
Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis? 99
Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects 98
Functional imaging in pre-motor Parkinson's disease 96
Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects 90
Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework 89
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers 88
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework 87
What predicts future cognitive decline in de novo Parkinson’s disease (PD)? 86
Direct correlation between cardiac and striatal F-18-DOPA uptake in de novo Parkinson's disease 85
Metabolic correlates of rey auditory verbal learning test in elderly subjects with memory complaints 85
Cortical structural covariance of nigro.striatal degeneration in dementia with Lewy bodies 84
Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques 84
Brain dopaminergic correlates of cognitive functions in de novo parkinson’s disease: a 18FDOPA PET study. 82
18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage 80
Predicting the transition from normal aging to Alzheimer's disease: A statistical mechanistic evaluation of FDG-PET data 80
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework 79
Performance of [18F] FDG-PET in 142 MCI patients with at least 2 years clinical follow up: a multicentric study of the European Alzheimer Disease Consortium (EADC) 77
Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly 72
null 70
Biomarkers validation in Alzheimer’s Disease and related pathologies 70
Lupus nephritis and Cyclic Vomiting Syndrome: a case report. 69
Neuroimaging Findings in Mild Cognitive Impairment 69
Dopaminergic Activity and Cognitive Function in de novo Parkinson Disease patients: an 18F-DOPA PET/CT study 67
Orbitofrontal (18) F-DOPA Uptake and Movement Preparation in Parkinson's Disease. 67
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease 67
Resting metabolic connectivity in Alzheimer's disease 62
Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study 61
Nigrocaudate dopaminergic impairment predict future cognitive decline in de novo parkinson’s disease (PD) 59
Functional neuroimaging in de novo Parkinson's disease with REM sleep behaviour disorder 58
Amygdalar nuclei and hippocampal subfields on MRI: test-retest reliability of automated volumetry across different MRI sites and vendors 56
Studio dell’attività serotoninergica troncoencefalica nel disturbo comportamentale del sonno REM. 54
White Matter Hyperintensities are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers 35
PSYCHOMETRIC PROPERTIES OF THE ITALIAN VERSION OF RESILIENCE SCALE IN ADULTS AND ELDERLY HEALTHY SUBJECTS 19
Totale 5.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.844
article - articoli 15.718
book - libri 0
conference - conferenze 1.214
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 687
Totale 35.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.292 0 0 0 104 120 169 209 127 131 245 142 45
2020/2021557 32 50 51 47 49 29 35 53 43 69 53 46
2021/2022703 23 20 52 81 23 67 31 167 50 62 22 105
2022/2023753 62 62 14 83 106 121 0 64 126 11 98 6
2023/2024422 20 42 8 59 39 88 18 37 19 5 19 68
2024/2025165 35 79 18 33 0 0 0 0 0 0 0 0
Totale 5.423